You are here
Extraordinary General Meeting held in NorDiag
18 June 2008: Attached are the minutes from the Extraordinary General Meeting in NorDiag held today, Wednesday June 18, 2008. 25,058,424 (65.4%) of outstanding shares were represented in the general meeting.
The main items on the agenda were the Board`s proposal for a rights issue of up to 25 002 457 new shares and terms for the company`s option scheme for employees.
The general meeting resolved the proposed rights issue. The subscription period is from June 26 to and including July 9, 2008.
The shareholders as of June 18 will receive 0.6254 subscription rights per share. The share will be traded exclusive subscription
rights from and including June 19, 2008.
The general meeting approved allocation of options with option price (strike) as the subscription price in the rights issue (NOK 2 per share).
Contact: CEO Mårten Wigstøl Phone. +47 911 65775
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com